A Look At All Of Pfizer's Acquisitions Over The Past 2 Years
Here is a look at some of Pfizer's completed acquisitions over the past two years.
On July 16, Pfizer acquired InnoPharma, a pharmaceutical development company with 10 generic products, for $225 million upfront and up to $135 million in milestone payments. The transaction was completed on September 25, 2014.
On December 1, Pfizer reported the closing of Baxter's Marked Vaccines Portfolio for $635 million.
On January 5, Pfizer announced it has acquired a controlling interest in Redvax GmbH, a privately held Swiss pharmaceutical company. As part of the transaction, Pfizer gained access to a preclinical human cytomegalovirus (CMV) vaccine candidate, as well as intellectual property and a technology platform related to a second, undisclosed vaccine program.
On February 5, Pfizer announced it has agreed to acquire Hospira for $90 a share, or $17 billion. Pfizer said that the deal would be immediately accretive to its full year earnings following the close of the transaction by $0.10 to $0.12 per share. The deal was closed on September 3.
On May 11, Pfizer said that it acquired a minority interest in AM-Pharma for $87.5 million upfront and up to $512.5 million in future payments. AM-Pharma biopharmaceutical company focused on the development of recombinant human Alkaline Phosphatase (recAP) for inflammatory diseases.
Various media sources reported in late October that Pfizer was eyeing an acquisition of Allergan plc Ordinary Shares (NYSE: AGN). A deal was announced on November 23 in which Pfizer would acquire Allergan for $160 billion. However, the deal was officially terminated on April 6, 2016 due to new measures by the U.S. Treasury to cut down on inversion-style acquisitions.
On January 13, Pfizer announced it has acquired Treerly and its family of Treerly products. Treerly is a China-based healthcare brand that focuses on nutritional healthcare needs for women.
On May 5, Reuters and other news sources reported that Pfizer has approached Medivation Inc (NASDAQ: MDVN) over a potential acquisition. A formal offer has not been disclosed.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.